Difference between revisions of "Cutaneous T-cell lymphoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''") |
Warner-admin (talk | contribs) m (Text replacement - "|Years of enrollment" to "|Dates of enrollment") |
||
| Line 15: | Line 15: | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
| − | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Revision as of 18:35, 25 March 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main CTCL page for current regimens.
Relapsed or refractory
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Prince et al. 2010 (L4389-11) | NR | Phase 3 (C) | Denileukin diftitox | Inferior PFS |
References
- L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains dosing details in manuscript PubMed NCT00050999